Balanced news tone
News Sentiment
688180 sentiment intelligence
Shanghai Junshi Biosciences Co., Ltd. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
92/100 classification confidence.
directly relevant articles
high-authority source matches
-6.6% over one week, +16.7% over four weeks, trend inactive, and near fair-value range.
Shanghai Junshi Biosciences Co., Ltd. Receives Acceptance Of Supplemental Application For Toripalimab In Combination With Chemotherapy As Perioperative Treatment For Resectable Stage II-III NSCLC Patients
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Shanghai Junshi Biosciences Co., Ltd. Receives Acceptance Of Supplemental Application For Toripalimab In Combination With Chemotherapy As Perioperative Treatment For Resectable Stage II-III NSCLC Patients
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jul 2026 14:35
- Source
- marketscreener.com
Junshi Biosciences Wins NMPA Nod to Expand Toripalimab Use in Early-Stage Lung Cancer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jul 2026 14:15
- Source
- TipRanks
What's Driving Junshi Biosciences' Recent Momentum
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 06:21
- Source
- Kavout | AI
Junshi Biosciences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 07:00
- Source
- Via Ritzau
Shanghai Junshi Biosciences Co., Ltd. Appoints Chen Liang as Independent Non-Executive Director and Announces Change in Composition of Board Committees, Effective June 26, 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 07:00
- Source
- marketscreener.com
Shanghai Junshi Biosciences Co., Ltd. Intends to Enter into the Joint Venture Agreement with Suzhou Union Biopharm Co., Ltd, Shanghai Junshi Biotechnology Co., Ltd, Suzhou Junmeng Biosciences Co., Ltd, Shanghai Ontarget Biopharmaceuticals Co., Ltd a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jun 2026 07:00
- Source
- marketscreener.com
Junshi Biosciences Announces Ongericimab’s sNDA Approval in China
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 27 May 2025 07:00
- Source
- Macau Business
Junshi Biosciences Aims to Raise $4.77 Million From International Share Sale
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 07 Jun 2023 07:00
- Source
- Caixin Global
Shanghai Junshi Biosciences Co., Ltd. Class A Balance Sheet – SSE:688180
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Apr 2021 07:32
- Source
- TradingView
AstraZeneca to Market Junshi Bio’s PD-1 Cancer Drug in China
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Mar 2021 08:00
- Source
- Caixin Global
1877.HK - Shanghai Junshi Biosciences Co., Ltd. Company Profile
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Aug 2020 09:26
- Source
- StockInvest.us
Shanghai Junshi Biosciences soars over 22% on HK debut | Gulf Times
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Dec 2018 08:00
- Source
- Gulf Times